Shareholders approve all board-proposed agenda itemsCumulative voting, electronic general meetings and the revision of the quarterly dividend record date so…
Results from the Phase 3 VELA clinical trials in adults with moderate-to-severe hidradenitis suppurativa (HS) show that clinical responses continue…
Poster #76954 highlights QTORIN™ rapamycin’s single phase anhydrous gel formulation designed to optimize dermal bioavailability of rapamycin for mTOR-driven skin…
Company Announcement no. 05/2026 Annual General Meeting 2026 Copenhagen, March 27, 2026 Annual General Meeting in cBrain A/SWednesday, April 29,…
Pursuant to Article 241-2 of the General Regulations of the French Financial Markets Authority (Autorité des marchés financiers – the…
Following End-of-Phase 2 meeting, MBX remains on track to initiate Phase 3 in Q3 2026 March 09, 2026 10:21 ET…
Positive results from Phase 3 ADAPT OCULUS study show VYVGART’s potential as the first targeted treatment for patients living with…
Châtillon, France, February 28, 2026 DBV Technologies Highlights Additional Data from Successful Phase 3 VITESSE Study at the AAAAI 2026…
February 28, 2026 09:45 ET | Source: Cogent Biosciences, Inc. Bezuclastinib mean TSS reduction deepens to –32.0 points at 48…
SAN DIEGO, Feb. 20, 2026 (GLOBE NEWSWIRE) -- ADARx Pharmaceuticals, Inc. (ADARx), a late-stage clinical biotechnology company developing next-generation RNA…